Beth Hollister

1.1k total citations
17 papers, 627 citations indexed

About

Beth Hollister is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Beth Hollister has authored 17 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Beth Hollister's work include Cancer therapeutics and mechanisms (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Neuroblastoma Research and Treatments (3 papers). Beth Hollister is often cited by papers focused on Cancer therapeutics and mechanisms (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Neuroblastoma Research and Treatments (3 papers). Beth Hollister collaborates with scholars based in United States, Netherlands and Japan. Beth Hollister's co-authors include Mark E. Davis, Jeremy D. Heidel, Jianjun Cheng, Derek W. Bartlett, Thomas Schluep, Jungyeon Hwang, Cheryl Napier, Steven A. Middleton, Stuart L. Emanuel and Catherine A. Rugg and has published in prestigious journals such as ACS Nano, Cancer Research and Clinical Cancer Research.

In The Last Decade

Beth Hollister

16 papers receiving 606 citations

Peers

Countries citing papers authored by Beth Hollister

Since Specialization

Citations

This map shows the geographic impact of Beth Hollister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Hollister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Hollister more than expected).

Fields of papers citing papers by Beth Hollister

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Hollister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Hollister. The network helps show where Beth Hollister may publish in the future.

Co-authorship network of co-authors of Beth Hollister

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Hollister. A scholar is included among the top collaborators of Beth Hollister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Hollister. Beth Hollister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation 2023 ·ACS Nano ·Aaron H. Colby, (unknown), Amit Patwa, Rong Liu, Beth Hollister, William McCulloch, Joanna E. Burdette, Cedric J. Pearce, (unknown), Yolonda L. Colson, Kebin Liu, Mark W. Grinstaff	11
2	Pilot-scale production of expansile nanoparticles: Practical methods for clinical scale-up 2021 ·Journal of Controlled Release ·Aaron H. Colby, Rong Liu, Robert P. Doyle, (unknown), Heng Zhang, Natasha M. Savage, Ngoc-Quynh Chu, Beth Hollister, William McCulloch, Joanna E. Burdette, Cedric J. Pearce, Kebin Liu, Nicholas H. Oberlies, Yolonda L. Colson, Mark W. Grinstaff	26
3	Small bowel and abdominal wall transplantation: A novel technique for synchronous revascularization 2019 ·American Journal of Transplantation ·Detlev Erdmann, (unknown), Brett T. Phillips, Suhail K. Mithani, Yash J. Avashia, Beth Hollister, Linda C. Cendales, Kadiyala V. Ravindra, Debra L. Sudan	10
4	Abstract LB-95: Estrogen receptor mRNA-directed therapy for triple-negative breast cancer 2014 ·Cancer Research ·(unknown), Laura A. Marlow, James L. Miller, (unknown), (unknown), Steadman D. Harrison, Beth Hollister, Derek C. Radisky, John A. Copland	0
5	Abstract LB-210: Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. 2013 ·Cancer Research ·(unknown), Laura A. Marlow, Thomas R. Caulfield, Kevin J. Wu, Winston Tan, Han W. Tun, John A. Copland, (unknown), (unknown), (unknown), Beth Hollister	1
6	Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies 2011 ·Alzheimer s Research & Therapy ·Diana W. Shineman, Guriqbal S. Basi, Jennifer L. Bizon, Carol A. Colton, Barry Greenberg, Beth Hollister, John Lincecum, Gabrielle G. Leblanc, (unknown), Feng Luo, Dave Morgan, (unknown), Lorenzo M. Refolo, David Riddell, Kimberly Scearce‐Levie, Patrick Sweeney, Juha Yrjänheikki, Howard Fillit	104
7	Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy 2010 ·Clinical Cancer Research ·Anil Bagri, Leanne Berry, Bert Gunter, Mallika Singh, Ian Kasman, Lisa A. Damico, Hong Xiang, Maike Schmidt, Germaine Fuh, Beth Hollister, Oliver Rosen, (unknown)	110
8	Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models 2010 ·Cancer Chemotherapy and Pharmacology ·(unknown), Robert P. Ryan, (unknown), Sheri M. Routt, Beth Hollister	6
9	Mechanistic evaluation of the combination effect of anti-VEGF and chemotherapy 2008 ·Cancer Research ·Ian Kasman, Anil Bagri, Judy Mak, Franklin Peale, (unknown), Jed Ross, Leanne Berry, (unknown), Patrick J. Rudewicz, Cary D. Austin, Ronald E. Ferrando, Sarajane Ross, Lisa Crocker, (unknown), (unknown), Kurt Scudder, Beth Hollister, (unknown)	3
10	MER-1001, a novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model 2007 ·Cancer Research ·(unknown), Mikhail Papisov, Alan J. Fischman, Alex Hiller, Mao Yin, (unknown), Stephen D. Harrison, (unknown), Kathleen Sheridan, Beth Hollister, Cheryl Napier, Ullrich Schwertschlag, Peter A. Leone, Julie S. Olson, Russell C. Petter	6
11	Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors 2007 ·Molecular Pharmacology ·Stuart L. Emanuel, Terry V. Hughes, Mary Adams, Catherine A. Rugg, Angel R. Fuentes‐Pesquera, Peter J. Connolly, Niranjan B. Pandey, (unknown), Jeannene Butler, Virna Borowski, Steven A. Middleton, Robert H. Gruninger, (unknown), Cheryl Napier, Beth Hollister, Lee M. Greenberger	30
12	Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models 2006 ·Clinical Cancer Research ·Thomas Schluep, Jungyeon Hwang, Jianjun Cheng, Jeremy D. Heidel, Derek W. Bartlett, Beth Hollister, Mark E. Davis	183
13	Mouse model of docetaxel neurotoxicity 2005 ·Cancer Research ·(unknown), (unknown), (unknown), George A. Parker, Cheryl Napier, Beth Hollister, Steadman D. Harrison	1
14	The In vitro and In vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases 2005 ·Cancer Research ·Stuart L. Emanuel, Catherine A. Rugg, Robert H. Gruninger, Ronghui Lin, Angel R. Fuentes‐Pesquera, Peter J. Connolly, Steven K. Wetter, Beth Hollister, (unknown), Cheryl Napier, Linda K. Jolliffe, Steven A. Middleton	101
15	Preclinical activity of an i.v. formulation of rubitecan in IDD-P™ against human solid tumor xenografts 2002 ·Anti-Cancer Drugs ·Howard Sands, (unknown), (unknown), Beth Hollister, Shih-Fong Chen	7
16	GEM 231, a second-generation antisense agent complementary to protein kinase A RIα subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts 2002 ·International Journal of Oncology ·Sudhir Agrawal, Ekambar R. Kandimalla, (unknown), (unknown), G Lombardi, (unknown), Daniel L. Dexter, Beth Hollister, Shih-Fong Chen	18
17	Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides 2001 ·International Journal of Oncology ·Sudhir Agrawal, Ekambar R. Kandimalla, Yu Dong, Beth Hollister, Shih-Fong Chen, Daniel L. Dexter, (unknown), (unknown), (unknown), Christine P. Bono, Deborah Knoerzer, (unknown)	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact